The FTC staff's second interim report finds that the three major pharmacy benefit managers hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer.
The report examines the impact of PBMs on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions.
The agency released its first interim staff report on PBMs in July, detailing how concentrated the PBM market has become, prompting investigations and legal actions.
While several healthcare executives support the report, the pharmacy benefit managers named in the report are decrying its findings, demonstrating a split in perspectives.
Collection
[
|
...
]